Through canonical and noncanonical pathways, ASPH inhibitors interrupt cell cycle progression by downregulating cyclin D1 and arresting cells in the G0/G1 cell cycle phase, thereby inhibiting the proliferation of cancer cells. This evidence concerns the gene ASPH and cancer.